|
|
|
By Life Science Connect Editorial Staff | Patient immune cells and varied raw materials introduce inherent biological variability into CAR-T therapy manufacturing, making it a constant balancing act of adjusting processes and technology to minimize batch-to-batch variability. |
|
|
|
In this excerpt from Cell & Gene Live's How To Reduce Batch-to-Batch Variation In Cell Therapy Manufacturing, experts share why changing from a manual process to an automated process is critical. |
|
|
|
|
|
|
| Setting Expectations For Post-Thaw Segment QC Testing On A CBU | Poster | Comprehensive Cell Solutions, A Business Unit of NYBC Enterprises | Review the post-thaw segment QC results for 2,249 consecutive segments cut at our institution to create a benchmark of what is to be expected when interpreting segment testing. |
|
|
| Overcoming Challenges In AAV And LV Viral Vector Manufacturing | White Paper | By Mathias Kahl, Stephan Bauer, Dr. Daniel Kohler, Dr. Tobias Thom, Rico Hinrichs, Stefan Borutzki, Christina Pospisil, Dr. Rico Schmidt, Erik Arnold, and Dr. Thomas Kreisig, IDT Biologika | Manufacturing viral vectors leaves sponsors vulnerable to high costs, delays, and the possibility of failure. The right CDMO partner can help you reduce timelines and costs for viral vector production. |
|
|
|
|
| The 6th Annual Allogeneic Cell Therapies Summit returns in June as the leading industry-focused meeting dedicated to accelerating the safety, durability, and clinical translation of off-the-shelf therapies to deliver affordable and accessible treatments for patients in critical need. Attend a jam-packed agenda of discussions that will help transform universal cell therapies for patients across the globe. Find out more here. |
|
|
|
|
|
|
| Connect With Cell & Gene: |
|
|
|
